ArticleCost effectiveness and resource allocation : C/E2020

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.

Herbert H Loong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.